Mayo Clinic researchers discover new immune system molecule that can help or harm health
Mayo Clinic researchers have identified a new member of the important B7 family of immune system "co-stimulators." Co-stimulators are molecules that are capable of turning the immune system on or off -- and in the process, profoundly affecting human health.
Mayo Clinic researchers named this newest molecule B7-H4. It inhibits the action of T cells, the immune system warriors whose basic job is to attack invaders. Turning off T cells helps transplant patients accept foreign organs. But turning off T cells harms cancer patients -- their tumors continue to grow without defensive attacks by T cells. The Mayo Clinic report appears in the June 17 issue of Immunity.
These findings may help researchers learn how to manipulate immune system co-stimulators to serve such therapeutic objectives as:
1) stopping the body from attacking itself in autoimmune diseases;
2) thwarting rejection of transplanted organs;
3) guiding the body to attack a cancer cell.
Significance of the Mayo Clinic Investigation
B7-H4 is the fourth in a line of so-called "co-stimulation" molecules discovered over five years of research led by Lieping Chen, M.D., Ph.D., professor of Immunology at Mayo Medical School. The first in the line, B7-H1, was discovered in 1999 by Dr. Chen and colleagues. And, as in so many families, the members of this molecule family bear intriguing differences. Chief among these differences: Not all B7 members serve the body the same way -- some boost the immune system, some blunt its effect and some do both, at different times, depending on the partner to which they bind and the pathways for action they create.
Says Dr. Chen, "The immune system is a double-edged sword. It can help and it can damage. It has a positive and a negative capacity -- and understanding and controlling these is the key issue for manipulation of diseases with new treatments. This molecule is very important for doing that work because it is a very potent negative regulation component of the immune system."
To examine the B7 group further, Mayo Clinic researchers analyzed genes in a database composed of members that were likely to be part of the B7 superfamily. Then they cloned the B7-H4 molecule, modeled it in 3-D on a computer and found the functional part of interest. Next, they engineered the molecule and tested its effects in T cells, both in cell culture and in live mice. They did this because Dr. Chens laboratory is probing the molecular basis of cellular communication to discover how different components of the immune system talk to each other on the cell surface. The basic exchange that occurs on the cell surface involves two parts: a receptor and its partner, which is called a "ligand." How these two parts interact determines the action the immune system takes.
Mayo Clinics Findings
B7-H4 is a very powerful "negative regulator," highly efficient at turning off T cells. This is important because in certain diseases, such as cancers, this regulator may be overly active. In healthy cells, there are no negative regulators. The implication: One reason healthy cells are healthy is that they dont have B7-H4 shutting down the T cells that police the body for invaders; their T cells are working and are protecting them. "In a tumor, you may have excess B7-H4 turning off T cells all the time. In a normal healthy body, the negative regulators like B7-H4 have to be turned on," says Dr. Chen. The mechanism by which B7-H4 inhibits T cells appears to be one of arresting cell division and the cell-proliferation cycle.
At a Glance Summary
- Some immune system molecules can go both ways: they can have the positive effect of boosting the immune system, or the negative effect of shutting it down -- or do both at different times -- depending on the nature of the partners to which they bind.
- B7-H4, the subject of Mayos current investigation, powerfully shuts down the immune system response of T cells.
- By discovering which molecules -- and which partners, or ligands -- are involved in turning the immune system on or off, Dr. Chen is confident Mayo Clinic research will help scientists devise new treatment strategies. "This new finding about B7-H4 adds excitement to the possibility of therapeutic manipulation of the immune system," he says.
Mary Lawson | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
What does it look like below the ice shelf of the calved massive iceberg A68?
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...